Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Radiation Injuries 3Pancreatic Neoplasms 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Vulvar Neoplasms 1Thymoma 1Thymic epithelial tumor 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Rare Diseases 1Pancreatic Cancer Non-resectable 1Ovarian Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1

Interventions

Blood Specimen Collection 38pembrolizumab 36Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 18Exercise 17Carboplatin 16Nivolumab 15atezolizumab 14Cisplatin 14Drug Therapy 13Paclitaxel 12Fluorouracil 12Cyclophosphamide 12Cetuximab 12Trastuzumab 10Leucovorin 10Docetaxel 10Dexamethasone 10Pemetrexed 9Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × Heavy Ion Radiotherapy × Clear all
NCT05203250 2025-08-06

Longitudinal Registry Including Patients Treated With Heavy Particles

CNAO National Center of Oncological Hadrontherapy

Recruiting
3,000 enrolled

Neoplasms, Radiation Injuries, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡